Serious adverse reactions in the PACE trial.

Serious adverse reactions occurring in > 2% of
patients in the PACE trial (N=449)
N (%)
Cardiovascular disorders

Arterial Occlusion
Cardiac vascular
Cerebrovascular
Peripheral vascular

 99 (22%)
53 (12%)
31 (7%)
34 (8%)
Venous thromboembolism 22 (5%)
Hemorrhage
CNS hemorrhage
Gastrointestinal hemorrhage		 28 (6%)
6 (1%)
11 (2%)
Heart failure 28 (6%)
Effusions (a) 15 (3%)
Atrial fibrillation 18 (4%)
Hypertension 12 (3%)
Gastrointestinal disorders
Pancreatitis 26 (6%)
Abdominal pain 20 (5%)
Blood and lymphatic system disorders
Febrile neutropenia 13 (3%)
Anemia 16 (3%)
Thrombocytopenia 14 (3%)
Infections
Pneumonia 32 (7%)
Sepsis 10 (2%)
General
Pyrexia 20 (5%)

(a) includes pericardial effusion, pleural effusion, and ascites